Clinical trial
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating…
NCT00328627 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00328627 |
|---|---|
| Title | Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus. |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Alogliptin, Alogliptin placebo, Pioglitazone, Pioglitazone placebo |
| Enrollment | 1,554 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | May 22, 2006 |
| Last update posted | Apr 4, 2013 |
| Countries | Australia, Brazil, Bulgaria, Chile, Croatia, Estonia, Guatemala, India, Israel, Latvia, Mexico, New Zealand and 7 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: